Sylvester Comprehensive Cancer Center

  • VSMART - Antoni, Michael

  • Investigator:
    Michael Antoni
    RCname Email

    		Coordinator:

    IRB: 20160525

    		SDG: Population Sciences
    Disease Site(s):

    Breast
    Sponsor: Florida Biomedical Research Program

    Enrolling Sites:

    JMH
    Sylvester
    Title:

    Stress Management Effects on Affective Status and Influenza Vaccine Response in Older Breast Cancer Patients.
    Eligibility Criteria - NCT03955991 *This information has been extracted from " www.clinicaltrials.gov"

  • TAPUR - Calfa, Carmen

  • Investigator:
    Carmen Calfa
    RCname Email

    		Coordinator:
    RCemailImg Carolina Troche
    RCphone +1 (305) 2431481

    IRB: 20170529

    		SDG: Breast Cancer
    Disease Site(s):

    Breast,Colon,Kaposis sarcoma,Kidney,Larynx,Liver,Lymphoid Leukemia,Multiple,Multiple Myeloma,Non-Hodgkin Lymphoma,Pancreas,Prostate,Soft Tissue
    Sponsor: ASCO

    Enrolling Sites:

    Aventura
    Deerfield
    Gables
    Kendall
    Plantation
    Sylvester
    Title:

    The Targeted Agent and Profiling Utilization Registry (TAPUR) Study
    Eligibility Criteria - NCT02693535 *This information has been extracted from " www.clinicaltrials.gov"

  • 20201046 - Calfa Carmen

  • Investigator:
    Carmen Calfa
    RCname Email

    		Coordinator:
    RCemailImg Deborah Conte
    RCphone 9542101171

    IRB: 20201046

    		SDG: Breast Cancer
    Disease Site(s):

    Breast
    Sponsor: ETCTN

    Enrolling Sites:

    Deerfield
    Gables
    Kendall
    Plantation
    Sylvester
    Title:

    Phase II Trial of Radium-223 Dichloride in Combination With Paclitaxel in Patients With Bone Metastatic Breast Cancer
    Eligibility Criteria - NCT04090398 *This information has been extracted from " www.clinicaltrials.gov"

  • 20210993 - Calfa Carmen

  • Investigator:
    Carmen Calfa
    RCname Email

    		Coordinator:
    RCemailImg Deborah Conte
    RCphone 9542101171

    IRB: 20210993

    		SDG: Breast Cancer
    Disease Site(s):

    Breast
    Sponsor: BRIACELL

    Enrolling Sites:

    Aventura
    Deerfield
    Gables
    Kendall
    Plantation
    Sylvester
    Title:

    A Phase I/IIa Study of the SV-BR-1-GM Regimen in Metastatic or Locally Recurrent Breast Cancer Patients in Combination With Retifanlimab and Epacadostat
    Eligibility Criteria - NCT03328026 *This information has been extracted from " www.clinicaltrials.gov"

  • CompassHER2-pCR - Dawar, Richa

  • Investigator:
    Richa Dawar
    RCname Email

    		Coordinator:

    IRB: 20200685

    		SDG: Breast Cancer
    Disease Site(s):

    Breast
    Sponsor: ECOG

    Enrolling Sites:

    Aventura
    Deerfield
    Gables
    Kendall
    Plantation
    Sylvester
    Title:

    (CompassHER2-pCR): Preoperative THP and postoperative HP in patients who achieve a pathologic complete response
    Eligibility Criteria - NCT04266249 *This information has been extracted from " www.clinicaltrials.gov"

  • 20200613 - Escobar Mauricio

  • Investigator:
    Mauricio Escobar
    RCname Email

    		Coordinator:

    IRB: 20200613

    		SDG: Breast Cancer
    Disease Site(s):

    Breast
    Sponsor: Hoffmann - La Roche

    Enrolling Sites:

    Deerfield
    Gables
    Plantation
    Sylvester
    Title:

    A Phase III Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating The Efficacy And Safety Of GDC-9545 Combined With Palbociclib Compared With Letrozole Combined With Palbociclib In Patients With Estrogen Receptor-Positive, Her2-Negative Locally Advanced Or Metastatic Breast Cancer
    Eligibility Criteria - NCT04546009 *This information has been extracted from " www.clinicaltrials.gov"

  • MATCH - Huang, Marilyn

  • Investigator:
    Marilyn Huang
    RCname Email

    		Coordinator:
    RCemailImg Carolina Troche
    RCphone +1 (305) 2431481

    IRB: 20150671

    		SDG: Gynecologic Cancer
    Disease Site(s):

    Cervix Uteri,Colon,Corpus Uteri,Kaposis sarcoma,Kidney,Larynx,Liver,Multiple Myeloma,Non-Hodgkin Lymphoma,Other Female Genital,Ovary,Pancreas,Prostate,Soft Tissue
    Sponsor: ECOG

    Enrolling Sites:

    Coral Springs
    Deerfield
    Gables
    Hollywood
    Kendall
    Plantation
    Sylvester
    Title:

    Molecular Analysis for Therapy Choice (MATCH)
    Eligibility Criteria - NCT02465060 *This information has been extracted from " www.clinicaltrials.gov"

  • 20201540 - Kesmodel Susan

  • Investigator:
    Susan Kesmodel
    RCname Email

    		Coordinator:
    RCemailImg Jornan Rodriguez Leyva
    RCphone +1 (305) 2432871

    IRB: 20201540

    		SDG: Breast Cancer
    Disease Site(s):

    Breast
    Sponsor: SCCC

    Enrolling Sites:

    Aventura
    Deerfield
    Gables
    Kendall
    Plantation
    Sylvester
    Title:

    Prospective Evaluation of Targeted Axillary Dissection After Neoadjuvant Systemic Therapy in Patients with Breast Cancer with Advanced Nodal Disease at Diagnosis
    Eligibility Criteria - NCT04998682 *This information has been extracted from " www.clinicaltrials.gov"

  • 20210732 - Krill Jackson Elisa

  • Investigator:
    Elisa Krill Jackson
    RCname Email

    		Coordinator:

    IRB: 20210732

    		SDG: Breast Cancer
    Disease Site(s):

    Breast
    Sponsor: Veru Inc.

    Enrolling Sites:

    Aventura
    Deerfield
    Gables
    Kendall
    Plantation
    Sylvester
    Title:

    ARTEST - A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Enobosarm Monotherapy Versus Active Control for the Treatment of AR+/ER+/HER2- Metastatic Breast Cancer in Patients with Androgen Receptor Nuclei Staining =40% Who Have Shown Previous Disease Progression on a Nonsteroidal Aromatase Inhibitor, Fulvestrant and CDK 4/6 inhibitor
    Eligibility Criteria - NCT04869943 *This information has been extracted from " www.clinicaltrials.gov"

  • RTX-240-01 - Merchan, Jaime

  • Investigator:
    Jaime Merchan
    RCname Email

    		Coordinator:
    RCemailImg Isabel Fernandez
    RCphone +1 (305) 2435486

    IRB: 20200686

    		SDG: Prostate, Bladder, and Kidney Cancers
    Disease Site(s):

    Multiple
    Sponsor: Rubius Therapeutics

    Enrolling Sites:

    Sylvester
    Title:

    PHASE 1/2 STUDY OF RTX-240 AS A MONOTHERAPY AND IN COMBINATION WITH PEMBROLIZUMAB
    Eligibility Criteria - NCT04372706 *This information has been extracted from " www.clinicaltrials.gov"

  • 20201537 - O'Neil Daniel

  • Investigator:
    Daniel O'Neil
    RCname Email

    		Coordinator:

    IRB: 20201537

    		SDG: Breast Cancer
    Disease Site(s):

    Breast
    Sponsor: Olema Pharmaceuticals

    Enrolling Sites:

    Deerfield
    Gables
    Plantation
    Sylvester
    Title:

    A Phase I Dose Escalation and Dose Expansion and Phase II Monotherapy Open-label, First-in-Human, Multicenter Study of OP-1250 in Adult Subjects with Advanced and/or Metastatic Hormone Receptor (HR)-positive, HER2-negative Breast Cancer
    Eligibility Criteria - NCT04505826 *This information has been extracted from " www.clinicaltrials.gov"

  • Tbio-6517-ITu-001 - Pimentel, Agustin

  • Investigator:
    Agustin Pimentel
    RCname Email

    		Coordinator:
    RCemailImg Rakhi Modak
    RCphone +1 (305) 2437387

    IRB: 20200277

    		SDG: Colorectal Cancer
    Disease Site(s):

    Multiple
    Sponsor: TSB

    Enrolling Sites:

    Sylvester
    Title:

    A Phase 1/2a, Multicenter, Open-label Trial of TBio-6517, an Oncolytic Vaccinia Virus, Administered Alone and in Combination with Pembrolizumab, in Patients with Advanced Solid Tumors
    Eligibility Criteria - NCT04301011 *This information has been extracted from " www.clinicaltrials.gov"

  • RPL-001-16 - Rodriguez, Estelamari

  • Investigator:
    Estelamari Rodriguez
    RCname Email

    		Coordinator:
    RCemailImg Yanel Diaz Caro
    RCphone 3052438227

    IRB: 20180802

    		SDG: Bone and Soft Tissue Cancers
    Disease Site(s):

    Bladder,Breast-Female,Colon,Melanoma, skin
    Sponsor: REPLIMUNE

    Enrolling Sites:

    Sylvester
    Title:

    RPL-001-16: An Open-Label, Multicenter, Phase 1/2 Study of RP1 as a Single Agent and in Combination with PD1 Blockade in Patients with Solid Tumors
    Eligibility Criteria - NCT03767348 *This information has been extracted from " www.clinicaltrials.gov"

  • SABER Study - Takita, Cristiane

  • Investigator:
    Cristiane Takita
    RCname Email

    		Coordinator:
    RCemailImg Zuzel Rodriguez
    RCphone +1 (305) 2430124

    IRB: 20190283

    		SDG: Breast Cancer
    Disease Site(s):

    Breast
    Sponsor: SCCC

    Enrolling Sites:

    Sylvester
    Title:

    Phase I Study to Evaluate the Safety and Feasibility of Preoperative Ablative Breast Radiotherapy (SABER) for Selected Early Stage Breast Cancer
    Eligibility Criteria - NCT04360330 *This information has been extracted from " www.clinicaltrials.gov"

  • MA.39: TAILOR RT - Takita, Cristiane

  • Investigator:
    Cristiane Takita
    RCname Email

    		Coordinator:
    RCemailImg Zuzel Rodriguez
    RCphone +1 (305) 2430124

    IRB: 20190405

    		SDG: Breast Cancer
    Disease Site(s):

    Breast
    Sponsor: CCTG

    Enrolling Sites:

    Deerfield
    Gables
    Sylvester
    Title:

    CCTG MA.39: A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive Breast Cancer
    Eligibility Criteria - NCT03488693 *This information has been extracted from " www.clinicaltrials.gov"

  • 20220017 - Takita Cristiane

  • Investigator:
    Cristiane Takita
    RCname Email

    		Coordinator:
    RCemailImg Samantha St. Armand

    IRB: 20220017

    		SDG: Breast Cancer
    Disease Site(s):

    Breast
    Sponsor: NRG

    Enrolling Sites:

    Deerfield
    Gables
    Sylvester
    Title:

    NRG-BR007: A Phase III Clinical Trial Evaluating De-Escalation Of Breast Radiation For Conservative Treatment Of Stage I, Hormone Sensitive, HER2-Negative, Oncotype Recurrence Score = 18 Breast Cancer
    Eligibility Criteria - NCT04852887 *This information has been extracted from " www.clinicaltrials.gov"

  • 20210118 - Valdes Frances

  • Investigator:
    Frances Valdes
    RCname Email

    		Coordinator:

    IRB: 20210118

    		SDG: Breast Cancer
    Disease Site(s):

    Breast
    Sponsor: Alliance for Clinical Trials in Oncology

    Enrolling Sites:

    Deerfield
    Gables
    Kendall
    Plantation
    Sylvester
    Title:

    The CompassHER2 Trials (Comprehensive Use of Pathologic Response Assessment to Optimize Therapy in HER2-Positive Breast Cancer) CompassHER2 Residual Disease (RD), a Double-Blinded, Phase III Randomized Trial of T-DM1 Compared With T-DM1 and Tucatinib
    Eligibility Criteria - NCT04457596 *This information has been extracted from " www.clinicaltrials.gov"

  • 20210996 - Valdes Frances

  • Investigator:
    Frances Valdes
    RCname Email

    		Coordinator:

    IRB: 20210996

    		SDG: Breast Cancer
    Disease Site(s):

    Breast
    Sponsor: Orinove Inc

    Enrolling Sites:

    Aventura
    Deerfield
    Gables
    Kendall
    Plantation
    Sylvester
    Title:

    A Phase 1/2, Open Label, Dose-Escalation and Expansion Study of Oral ORIN1001 With and Without Chemotherapy in the Treatment of Subjects With Solid Tumors.
    Eligibility Criteria - NCT03950570 *This information has been extracted from " www.clinicaltrials.gov"